447 results on '"Link-Gelles, Ruth"'
Search Results
2. Advancing public health informatics during the COVID-19 pandemic: Lessons learned from a public–private partnership with pharmacies
3. Use of an Additional Updated 2023-2024 COVID-19 Vaccine Dose for Adults Aged [greater than or equal to]65 Years: Recommendations of the Advisory Committee on Immunization Practices--United States, 2024
4. Number needed to vaccinate with a COVID-19 booster to prevent a COVID-19-associated hospitalization during SARS-CoV-2 Omicron BA.1 variant predominance, December 2021–February 2022, VISION Network: a retrospective cohort study
5. Estimated COVID-19 vaccine effectiveness against seroconversion from SARS-CoV-2 Infection, March–October, 2021
6. Interim Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19-Associated Hospitalization Among Adults Aged [greater than or equal to]18 Years with Immunocompromising Conditions--VISION Network, September 2023-February 2024
7. Interim Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalization Among Immunocompetent Adults Aged [greater than or equal to]18 Years--VISION and IVY Networks, September 2023- January 2024
8. Interim Estimates of 2023-24 Seasonal Influenza Vaccine Effectiveness--United States
9. Early Estimates of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Attributable to Co-Circulating Omicron Variants Among Immunocompetent Adults--Increasing Community Access to Testing Program, United States, September 2023-January 2024
10. Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing COVID-19- Related Thromboembolic Events Among Medicare Enrollees Aged [greater than or equal to] 65 Years and Those with End Stage Renal Disease--United States, September 2022-March 2023
11. Development of COVID-19 vaccine policy — United States, 2020–2023
12. Challenges and opportunities during the COVID-19 vaccination efforts in long-term care
13. Building the U.S. COVID-19 vaccine effectiveness program: Past successes and future directions
14. Use of an Additional Updated 2023–2024 COVID-19 Vaccine Dose for Adults Aged ≥65 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024
15. Use of Updated COVID-19 Vaccines 2023-2024 Formula for Persons Aged [greater than or equal to] 6 Months: Recommendations of the Advisory Committee on Immunization Practices--United States, September 2023
16. Community-Based Services to Improve Testing and Linkage to Care Among Non-U.S.-Born Persons with Chronic Hepatitis B Virus Infection - Three U.S. Programs, October 2014-September 2017.
17. Interim Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19–Associated Hospitalization Among Adults Aged ≥18 Years with Immunocompromising Conditions — VISION Network, September 2023–February 2024
18. Challenges and opportunities during the COVID-19 vaccination efforts in long-term care
19. Ecological Analysis of the Decline in Incidence Rates of COVID-19 Among Nursing Home Residents Associated with Vaccination, United States, December 2020-January 2021
20. Limited Secondary Transmission of SARS-CoV-2 in Child Care Programs — Rhode Island, June 1–July 31, 2020
21. Characteristics Associated with Hospitalization Among Patients with COVID-19 — Metropolitan Atlanta, Georgia, March–April 2020
22. National Update on Measles Cases and Outbreaks — United States, January 1–October 1, 2019
23. Characteristics and Risk Factors of Hospitalized and Nonhospitalized COVID-19 Patients, Atlanta, Georgia, USA, March-April 2020
24. Generalisability of vaccine effectiveness estimates: an analysis of cases included in a postlicensure evaluation of 13-valent pneumococcal conjugate vaccine in the USA.
25. Bias with respect to socioeconomic status: A closer look at zip code matching in a pneumococcal vaccine effectiveness study
26. Referrals of Infection Control Breaches to Public Health Authorities: Ambulatory Care Settings Experience, 2017
27. Screening and linkage to care for hepatitis C among inpatients in Georgia's national hospital screening program
28. National update on measles cases and outbreaks — United States, January 1 – October 1, 2019
29. 2365. Effectiveness of COVID-19 Vaccines Against Medically Attended COVID-19 in Pregnant Persons Within the VISION Network, December 2021 - April 2023
30. Impact of accounting for correlation between COVID-19 and influenza vaccination in a COVID-19 vaccine effectiveness evaluation using a test-negative design
31. Use of Updated COVID-19 Vaccines 2023–2024 Formula for Persons Aged ≥6 Months: Recommendations of the Advisory Committee on Immunization Practices — United States, September 2023
32. Update : Recommendations of the Advisory Committee on Immunization Practices for Use of Hepatitis A Vaccine for Postexposure Prophylaxis and for Preexposure Prophylaxis for International Travel
33. Interim Recommendations for Use of Bivalent mRNA COVID-19 Vaccines for Persons Aged [greater than or equal to]6 Months--United States, April 2023
34. Estimates of Bivalent mRNA Vaccine Durability in Preventing COVID-19--Associated Hospitalization and Critical Illness Among Adults with and Without Immunocompromising Conditions--VISION Network, September 2022-April 2023
35. Characteristics of Patients with Acute Flaccid Myelitis, United States, 2015-2018
36. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance
37. Preliminary Estimates of Effectiveness of Monovalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection Among Children Aged 3-5 Years--Increasing Community Access to Testing Program, United States, July 2022-February 2023
38. Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5-- and XBB/XBB.1.5--Related Sublineages Among Immunocompetent Adults-- Increasing Community Access to Testing Program, United States, December 2022-January 2023
39. Interim Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19-Associated Hospitalization Among Adults Aged =18 Years with Immunocompromising Conditions -- VISION Network, September 2023-February 2024.
40. Risk of COVID‐19 Hospitalization and Protection Associated With mRNA Vaccination Among US Adults With Psychiatric Disorders.
41. Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing COVID-19-Related Thromboembolic Events Among Medicare Enrollees Aged ≥65 Years and Those with End Stage Renal Disease -- United States, September 2022-March 2023.
42. Vaccine Effectiveness of the Original Monovalent COVID-19 Vaccines in preventing Emergency Department or Urgent Care Encounters and Hospitalizations among Adults with Disabilities: VISION Network, June 2021-September 2022
43. Application of a life table approach to assess duration of BNT162b2 vaccine-derived immunity by age using COVID-19 case surveillance data during the Omicron variant period
44. Clinical Epidemiology and Risk Factors for Critical Outcomes Among Vaccinated and Unvaccinated Adults Hospitalized With Coronavirus Disease 2019—VISION Network, 10 States, June 2021–March 2023
45. Effectiveness of Monovalent and Bivalent mRNA Vaccines in Preventing COVID-19–Associated Emergency Department and Urgent Care Encounters Among Children Aged 6 Months–5 Years — VISION Network, United States, July 2022–June 2023
46. Estimates of Bivalent mRNA Vaccine Durability in Preventing COVID-19–Associated Hospitalization and Critical Illness Among Adults with and Without Immunocompromising Conditions — VISION Network, September 2022–April 2023
47. Community-Based Services to Improve Testing and Linkage to Care Among Non–U.S.-Born Persons with Chronic Hepatitis B Virus Infection — Three U.S. Programs, October 2014–September 2017
48. Increase in Hepatitis A Virus Infections — Marshall Islands, 2016–2017
49. Recommendations of the Advisory Committee on Immunization Practices for Use of a Hepatitis B Vaccine with a Novel Adjuvant
50. Use of hepatitis A vaccine for post-exposure prophylaxis in individuals over 40 years of age: A systematic review of published studies and recommendations for vaccine use
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.